Skip to main content
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Clinical Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • Quality Improvement Sucess Stories
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • Clinical Compendia
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
  • Advertising
  • Reprints/Reuse
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Instructions for Authors
    • ADA Journal Policies
  • More from ADA
    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
  • Browse
    • Issue Archive
    • Saved Searches
    • COVID-19 Article Collection
    • Quality Improvement Sucess Stories
    • ADA Standards of Medical Care
    • ADA Standards of Medical Care, Abridged
    • Clinical Compendia
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
  • Advertising
  • Reprints/Reuse
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • Instructions for Authors
    • ADA Journal Policies
Departments

Third-Party Reimbursement: Now Comes the Really Difficult Part

  1. Steven B. Leichter, MD, FACP, FACE
    Clinical Diabetes 2003 Oct; 21(4): 181-182. https://doi.org/10.2337/diaclin.21.4.181
    PreviousNext
    • Article
    • Info & Metrics
    • PDF
    Loading

    The establishment of federally mandated benefits for diabetes supplies1 and educational services2 has opened a new era of opportunity for diabetic people. These guidelines permit diabetic Americans access to at least some supplies for home glucose monitoring, and, under specific but widely applicable clinical circumstances, access to diabetes patient education. Because the provision of patient education services has been tied by Medicare regulations to Education Recognition by the American Diabetes Association (ADA), the system includes assurance of reasonable quality for these services. In addition, these precedents set by Medicare increase the likelihood that voluntary advocacy may encourage similar coverage for diabetic people from other health insurers. These advances are all significant and are discussed further in the ADA position statement, “Third-Party Reimbursement for Diabetes Care, Self-Management Education, and Supplies,” which is reprinted in this issue (p. 183).

    However, they come at a time of new and growing challenges to the adequate provision of care for diabetic Americans, especially older Americans. These challenges may affect the availability not only of the very benefits that have been specifically mandated by Medicare, but also of essential health care itself. Given the potential significance of these issues, it seems important that we all become versed in them and watchful of trends that may raise concern.

    As discussions have noted in this journal and others,3–6 diabetes care, as described by accepted national guidelines,7 is often complex and costly to provide. In part, the cost and complexity reflect the variety of services that diabetic patients need and should have in the provision of routine care, including physician care, ongoing instruction in self-care, and nutrition counseling. Such services are frequently necessary even during the most routine office visits. However, they increase the cost of rendering care because they lengthen visits and, in many office settings, require a more intense use of personnel per visit.

    This cost structure for diabetes care has not been met by ongoing changes in insurance reimbursement for that care. Despite the higher cost of service for diabetic patents, there is no premium paid by insurers for their care versus the care of other, less costly patient groups. Insurers, working with the ADA, have defined positive guidelines for the care of diabetic people.7,8 Although attention to these guidelines increases the cost and complexity of care, providers receive no incentives or rewards for meeting those guidelines. Thus, financial analyses of the office care of diabetic people have noted that the current system of reimbursement encourages physicians to do less—not more—for their diabetic patients or to avoid the care of diabetic people altogether.

    Until recently, these fiscal issues in the outpatient care of diabetic people seemed theoretical and ameliorated by the much stronger concern of most physicians and other providers for the welfare of their patients first. However, trends arising during the past 2 years suggest that these concerns may merit closer attention now. In that time frame, physician reimbursements for office medical care by Medicare have been reduced by 12%. An increasing number of doctors have either limited the number of Medicare recipients in their practices or excluded Medicare clients from their practices.

    A similar, if not worse, situation exists with regard to Medicaid patients. Medicaid reimbursement for nonsurgical outpatient care is quite low in many states. In some states, physician participation in the Medicaid program has declined significantly. Because diabetic patients as a group have a lower socio-economic status than do nondiabetic patients,9 physician participation in Medicaid programs is relevant to the availability and degree of excellence of diabetes care for eligible participants.

    Physicians are also becoming more concerned about demands for services for which there is no compensation or for which there is a substantial “hassle factor.” Lack of compensation for completion of multiple administrative forms with or without added administrative and legal worries obstructs patient access to supplies and services related to those documents. This is the case with access to diabetes supplies and, to a lesser degree, diabetes patient education services.

    There is a peculiarity in the Medicare regulations for diabetes supplies that constitutes a severe hassle factor for physicians. It states that, if a provider approves diabetes supplies for the same patient in duplicate (i.e., during a defined time period), the provider, and not the supplier, is guilty of fraud and abuse and may be subject to a fine. The national suppliers of diabetes testing materials and other items offer providers no guarantee that they will not be asked to authorize supplies in duplicate (personal communication, Liberty Medical Company). They are concerned only that they have provider authorization to ship the customer supplies rather than that they protect the potential legal liability of the provider. Thus, providers have to maintain some sort of record-keeping system to prevent duplicate authorization without compensation.

    The broad implication of these trends suggests a need to become watchful about whether the realities of the reimbursement scheme attract providers to engage in diabetes care and encourage them to offer the best care. If these trends progress in a negative fashion, the outcome may be to reduce the interest of providers to deliver diabetes care. The risks are especially pronounced for Medicare patients.

    Similarly, we should keep in mind the realities facing the providers who approve diabetes supplies and education. If the act of authorizing diabetes supplies puts the provider at risk for a substantial fine, clearly that is a problem that merits our attention. These concerns may be at least as important as our advocacy to expand the access of diabetic people to the many other services and supports they deserve to help them contend with this life-long condition.

    Footnotes

    • Steven B. Leichter, MD, FACP, FACE, is co-director of the Columbus Research Foundation in Columbus, Ga., and a professor of medicine at Mercer University School of Medicine in Macon, Ga.

    • American Diabetes Association

    References

    1. ↵
      Health Care Financing Administration: “Diabetes.” Department of Health and Human Services, Washington, D.C. 2002. Located online at http://cms.hhs.gov/medlearn/diabetes_brochure.pdf
    2. ↵
      Health Care Financing Administration: Medicare Intermediary Manual. Part 3: Claims Process. U.S. Department of Health and Human Services, Washington, D.C. 2001, p. 3618
    3. ↵
      Leichter SB: Costs and reimbursements as determinants of the quality of diabetes care: I. Direct cost determinants. Clin Diabetes 19:42–44, 2001
    4. Leichter SB: Costs and reimbursements as determinants of the quality of diabetes care: II. Indirect influences on cost. Clin Diabetes 19:148–150, 2001
      OpenUrlFREE Full Text
    5. Leichter SB: Costs and reimbursements as determinants of the quality of diabetes care: III. Reimbursement determinants. Clin Diabetes 20:43–44, 2002
      OpenUrlFREE Full Text
    6. ↵
      Brandle M, Zhou H, Smith BRK, Marriott D, Burke R, Tabaei BP, Brown MR, Herman WH: The direct medical cost of type 2 diabetes. Diabetes Care 26:2300–2304, 2003
      OpenUrlAbstract/FREE Full Text
    7. ↵
      American Diabetes Association. Clinical Practice Recommendations 2003. Diabetes Care 26 (Suppl. 1) S1–S143, 2003
      OpenUrlCrossRef
    8. ↵
      American Medical Association, Joint Commission on Accreditation Healthcare Organizations, and the National Committee for Quality Assurance: Coordinated performance measurement for the management of adult diabetes. www.ama-assn.org/ama/pub/category/3798.html.
    9. ↵
      Cowie CC, Eberhardt MS: Sociodemographic characteristics of persons with diabetes. In Diabetes in America. 2nd ed. Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH, Eds. Washington, D.C., U.S. Govt. Printing Office, 1995 (NIH publ. no. 95-1468), p. 85–116
    PreviousNext
    Back to top

    In this Issue

    October 2003, 21(4)
    • Table of Contents
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Clinical Diabetes.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Third-Party Reimbursement: Now Comes the Really Difficult Part
    (Your Name) has forwarded a page to you from Clinical Diabetes
    (Your Name) thought you would like to see this page from the Clinical Diabetes web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Third-Party Reimbursement: Now Comes the Really Difficult Part
    Steven B. Leichter
    Clinical Diabetes Oct 2003, 21 (4) 181-182; DOI: 10.2337/diaclin.21.4.181

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    Third-Party Reimbursement: Now Comes the Really Difficult Part
    Steven B. Leichter
    Clinical Diabetes Oct 2003, 21 (4) 181-182; DOI: 10.2337/diaclin.21.4.181
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Footnotes
      • References
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    Departments

    • Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients
    • Gvoke HypoPen: An Auto-Injector Containing an Innovative, Liquid-Stable Glucagon Formulation for Use in Severe Acute Hypoglycemia
    • Timely News and Notes for Primary Care Providers from the American Diabetes Association
    Show more Departments

    Commentary

    • Suggestions to Overcome Racial Inequities Among Health Care Professionals
    • Expanding Flash Continuous Glucose Monitoring Technology to a Broader Population
    • Reflection (With Some Coaching) on a Quality Improvement Initiative: Finding Our Collective Voice Along the Journey
    Show more Commentary

    Similar Articles

    Navigate

    • Current Issue
    • Papers in Press
    • Abridged Standards of Care
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes
    • Diabetes Care
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Clinical Diabetes Print ISSN: 0891-8929, Online ISSN: 1945-4953.